---
title: 'The Niche Episode 054 – Aduhelm + Alzheimer’s, Regeneron Execs, CROS NT + Alira Health, FDA Recall'
type: 'episode'
url: 'https://doc.social/episodes/the-niche-episode-054-aduhelm-alzheimers-regeneron-execs-cros-nt-alira-health-fda-recall'
show: 'Life Science Today'
show_url: 'https://doc.social/podcasts/life-science-today'
published: '2021-06-14'
audio: 'unavailable — the host retired the file'
---

# The Niche Episode 054 – Aduhelm + Alzheimer’s, Regeneron Execs, CROS NT + Alira Health, FDA Recall

We dive deep into Alzheimer’s, Regeneron execs might be overpaid, a merger in clinical research, and the FDA issues a Class 1 recallSponsorshttps://www.thescopemethod.comStory Referenceshttps://tinyurl.com/Niche-054-1https://tinyurl.com/Nic…

## Summary

We dive deep into Alzheimer’s, Regeneron execs might be overpaid, a merger in clinical research, and the FDA issues a Class 1 recall

**Sponsors
**[https://www.thescopemethod.com](https://www.thescopemethod.com)

**Story References
**[https://tinyurl.com/Niche-054-1](https://tinyurl.com/Niche-054-1)
[https://tinyurl.com/Niche-054-2](https://tinyurl.com/Niche-054-2)
[https://tinyurl.com/Niche-054-3](https://tinyurl.com/Niche-054-3)
[https://tinyurl.com/Niche-054-4](https://tinyurl.com/Niche-054-4)
[https://tinyurl.com/Niche-054-5](https://tinyurl.com/Niche-054-5)

** Music by Luke Goodson
**[https://www.soundcloud.com/lukegoodson](https://www.soundcloud.com/lukegoodson)

The Niche Podcast brings you interviews with industry experts and top stories from last week in biotech, pharma, clinical research, and the life science industries. You can expect highlights about new technologies, biotech and pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to IPOs. The Niche also tries to highlight trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed, move through clinical trials, and become approved by regulatory agencies. It’s news, with a dash of perspective, focused on these Niche industries.